NIH SPECIAL SCIENCE SERIES: Novel Mouse Strain for Therapeutic Compound Screening for Human Age-Related Macular Degeneration (AMD)

Share Article

In this webinar, Dr. Chi Chao Chan presents the causes and treatments for AMD, as well as a model organism for human age-related macular degeneration (AMD).

This novel discovery includes a double deficient mouse strain for therapeutic compound screening for human age-related macular degeneration (AMD).

This novel discovery includes a double deficient mouse strain for therapeutic compound screening for human age-related macular degeneration (AMD).

In this webinar, Dr. Chi Chao Chan presents the causes and treatments, as well as a model organism for human age-related macular degeneration (AMD).

One Million Solutions in Health announces an opportunity to utilize science from the NIH which offers a novel mouse strain for therapeutic compound screening for human age-related macular degeneration (AMD).

One Million Solutions in Health has partnered with the United States' National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) and is seeking to spread awareness of NIH technologies and advances.

In this One Million Solutions in Health webinar entitled "NIH Special Science Series: Novel Mouse Strain for Therapeutic Compound Screening for Human Age-Related Macular Degeneration (AMD)" end users are provided with the opportunity to acquire knowledge about the latest science and technology directly from NIH scientists themselves. Users can also take part in One Million Solutions in Health's exclusive Signature Square process where they are able to assess the innovation, make inquiries and give open feedback to the scientists.

Dr. Chi Chao Chan has developed a strain of mice as a model organism to research age-related macular degeneration (AMD). Currently, AMD is the most prevalent form of irreversible blindness worldwide in the elderly population. To discuss the cause of AMD, as well as treatments, a model organism is needed. She presents a model which been tested and proven to be successful.

This novel discovery includes a double deficient mouse strain for therapeutic compound screening for human age-related macular degeneration (AMD). These mice develop focal retinal degeneration with early inception (4-6 weeks) and high penetrance (100% retinal lesions). The focal retinal lesions include photoreceptor and retinal pigment epithelial degeneration, a trademark of AMD pathology in the human macular arena.

To understand the power and potential behind this technology, it is important to understand that universally AMD is the principal cause of irreversible central blindness in the elderly population. A study funded by the U.S. Centers for Disease Control and Prevention reveals that as many as 9.1 million people had age-related macular degeneration (AMD) in 2010, with this figure predicted to double by 2050.

This innovative technology seeks to provide a model with high penetrance and early onset of human age-related macular degeneration. Presently, the exact mechanism of AMD is still under investigation and there is no distinct model for reviewing the full medical features of AMD.

This model is already being used by Sanofi and Allergan for AMD testing, and can significantly contribute to healthcare by testing drug discovery and development processes of AMD.

The Signature Square program includes organizations such as Pfizer, AbbVie, Amgen and Allergan, and many others.

ABOUT ONE MILLION SOLUTIONS IN HEALTH

The goal of One Million Solutions in Healthâ„¢ is to shape health care by sharing solutions and, importantly, to accelerate the discovery, development and delivery ... of innovative cures, treatments and preventative measures for patients around the world.

In this next year, we will be reviewing 1000's of new solutions and new scientific discoveries. By engaging scientists, entrepreneurs, investors, innovators, industry experts, health care professionals, and patients across various disciplines, and from around the world, we can utilize the power of the internet to disrupt things in a positive and transformative way to accelerate the movement of new solutions and scientific discoveries from the scientist to the patient.

We are on our way towards accelerating high-potential innovations, catalyzing investment and increasing awareness of, and support for, transformative ideas to improve health and save lives. By facilitating efforts to ensure organizations can Connect, Learn + Share, Innovate and Collaborate, our vision is to improve health care delivery, accelerate life sciences research, and share patient and consumer-focused ideas and solutions.

As a not-for-profit, we welcome your participation and are thrilled to have you be a part of this transformative journey!

MEDIA CONTACT:
Dawn Van Dam
Executive Director and CEO
dawn.vandam (at) onemillionsolutionsinhealth.org
http://www.onemillionsolutionsinhealth.org

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dawn Van Dam
@1MilSolutionsIn
since: 04/2012
Follow >
One Million Solutions in Health
since: 06/2012
Like >
One Million Solutions in Health

Follow us on
Visit website